Amgen will rely on the emergence of its newer products in 2026 to overcome the loss of exclusivity of a few of its big sellers. Carrying a heavy load in the first quarter for Amgen was cholesterol-lowering drug Repatha, which was up 34% with sales reaching $876 million.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
